WO2025141513 - COMPOSITIONS AND METHODS OF A CONCOMITANT THERAPY OF ALTERNATING ELECTRIC FIELDS AND NOTCH-1 INHIBITOR OR HES5 INHIBITOR
National phase entry is expected:
Publication Number
WO/2025/141513
Publication Date
03.07.2025
International Application No.
PCT/IB2024/063222
International Filing Date
27.12.2024
Title **
[English]
COMPOSITIONS AND METHODS OF A CONCOMITANT THERAPY OF ALTERNATING ELECTRIC FIELDS AND NOTCH-1 INHIBITOR OR HES5 INHIBITOR
[French]
COMPOSITIONS ET MÉTHODES DE THÉRAPIE CONCOMITANTE PAR CHAMPS ÉLECTRIQUES ALTERNATIFS ET INHIBITEUR DE NOTCH-1 OU INHIBITEUR DE HES5
Applicants **
NOVOCURE GMBH
Inventors
HAI, Jiang
ZHUANG, Dongxiao
HONG, Pengjie
Priority Data
63/615,418
28.12.2023
US
63/726,002
27.11.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2363 | |
| EPO | Filing, Examination, Granting | 9183 | |
| Japan | Filing, Examination, Granting | 2154 | |
| South Korea | Filing, Examination, Granting | 2099 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
20,539
Contact Us
Abstract[English]
Disclosed are methods of treating a subject in need thereof comprising applying an alternating electric field, to a target site of the subject in need thereof; and administering a a Notch1 inhibitor or Hes5 inhibitor to the subject in need thereof. Disclosed are methods of preventing cancer recurrence in a subject having cancer comprising: applying an alternating electric field to a target site of the subject in need thereof; and administering a Notch1 inhibitor or Hes5 inhibitor to the subject in need thereof. Disclosed are methods of reducing cancer cell growth comprising: applying an alternating electric field to a population of cells comprising one or more cancer cells; and contacting a Notch1 inhibitor or Hes5 inhibitor to the population of cells. Disclosed are methods of sensitizing cancer cells to an alternating electric field comprising: applying an alternating electric field to a population of cells comprising one or more cancer cells; and contacting a Notch1 inhibitor or Hes5 inhibitor to the population of cells.[French]
La divulgation concerne des méthodes de traitement d'un sujet en ayant besoin, comprenant l'application d'un champ électrique alternatif, à un site cible du sujet en ayant besoin ; et l'administration d'un inhibiteur de Notch1 ou d'un inhibiteur de Hes5 au sujet en ayant besoin. L'invention concerne des méthodes de prévention de la récidive du cancer chez un sujet atteint d'un cancer consistant en : l'application d'un champ électrique alternatif à un site cible du sujet en ayant besoin ; et l'administration d'un inhibiteur de Notch1 ou d'un inhibiteur de Hes5 au sujet en ayant besoin. L'invention concerne des méthodes de réduction de la croissance de cellules cancéreuses consistant en : l'application d'un champ électrique alternatif à une population de cellules comprenant une ou plusieurs cellules cancéreuses ; et la mise en contact d'un inhibiteur de Notch1 ou d'un inhibiteur de Hes5 avec la population de cellules. L'invention concerne des méthodes de sensibilisation de cellules cancéreuses à un champ électrique alternatif consistant en : l'application d'un champ électrique alternatif à une population de cellules comprenant une ou plusieurs cellules cancéreuses ; et la mise en contact d'un inhibiteur de Notch1 ou d'un inhibiteur de Hes5 avec la population de cellules.